

**March 03, 2023**

National Stock Exchange of India Limited,  
Exchange Plaza, Bandra Kurla Complex,  
Bandra (E), Mumbai-400051, MH.

BSE Limited  
Phiroze Jeejeebhoy Towers  
Dalal Street, Fort, Mumbai-400001

Symbol: **ORCHPHARMA**

Scrip Code: **524372**

**Subject: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Orchid Pharma Limited**

Dear Sir/Madam,

This is in continuation to our earlier letter dated July 16, 2022 w.r.t. the approval granted to Orchid-Bio Pharma Ltd (wholly owned subsidiary) by Competent Authority under the Production Linked Incentive (PLI) Scheme for manufacturing of product "7 ACA".

In the matter, we would like to inform you that our Company and Orchid Bio Pharma Limited has entered into a Memorandum of Understanding ("MoU") with an overseas technology provider for in-licensing 7ACA technology.

You are requested to take the above information on your record.

For Orchid Pharma Limited

*Marina*

**Marina Peter**  
Company Secretary

